HOXA11-AS has been reported to have roles in various different cancers, including breast cancer, lung cancer, ovarian cancer, gastric cancer, colorectal cancer, glioma, and cervical cancer. Some studies have indicated that lncRNAs can be markers or targeted for treatment in various types of cancers. Tissue samples of patients with breast cancer show high expression levels of HOXA11-AS, indicating its carcinogenic nature. Evidence of over-expression of HOXA11-AS as a causative factor of cell proliferation is seen when proliferation is blocked, once the lncRNA expression is knocked-down, or removed. Manipulating or removing the expression of this lncRNA allowed scientists to halt the progression of the cell cycle and initiate cell apoptosis at common cellular checkpoints, such as G1/G0 stage. The expression of the lnRNA was also suppressed by using small interfering RNAs (siRNA), that would degrade HOXA11-AS lnRNA transcripts. Upon doing so, cell proliferation was blocked. In addition to interfering with proliferation, degradation of HOXA11-AS lncRNA with siRNA was also seen to influence cell migration and cell tumor invasion, which is cancer metastasis. Scientists were able to determine these effects of HOXA11-AS lncRNA on breast cancer by monitoring the changes of epithelial-mesenchymal markers in the cell. Current research is looking at the potential possibility that breast cancer can be controlled or blocked by regulating the interaction between the lnRNA and epithelium/mesenchyme. In non-small cell lung cancers (NSCLC), researchers found that HOXA11-AS plays a role as an oncogene, and that patients who had decreased HOXA11-AS lncRNA had a greater survival time. In addition, HOXA11-AS lncRNA was found to be up-regulated in the lung tissue of patients with NSCLC. HOXA11-AS lncRNA was found to inhibit apoptosis, promote cancer cell proliferation, promote cell migration, and activate the cell cycle. HOXA11-AS lncRNA is studied in cancer research since its over-expression has been reported in epithelial ovarian cancer (EOC). In addition, on the molecular level, single nucleotide polymorphisms (SNPs) have also been observed in the lncRNA sequences of HOXA11-AS in EOC patients. Studies have shown that the SNP variants in these lncRNA sequences do not increase risk of EOC in patients, but may be the driving force of the cancer phenotype.